A Pim kinase inhibitor, please

被引：6

作者：

Giles, F ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2005年 / 105卷 / 11期

关键词：

D O I：

10.1182/blood-2005-03-1150

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hammerman and colleagues have shown that the Pim-2 kinase is required to confer rapamycin resistance in hematopoietic cells, thus providing a strong rationale for the development of Pim kinase inhibitors as potential therapeutic agents in hematologic malignancies.

引用

收藏

页码：4158 / 4159

页数：2

相关论文

共 5 条

[1] Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma [J].

Cohen, AM ;

Grinblat, B ;

Bessler, H ;

Kristt, DA ;

Kremer, A ;

Shalom, S ;

Schwartz, A ;

Halperin, M ;

Merkel, D ;

Don, J .

LEUKEMIA & LYMPHOMA, 2004, 45 (05) :951-955

[2] The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor [J].

Fox, CJ ;

Hammerman, PS ;

Cinalli, RM ;

Master, SR ;

Chodosh, LA ;

Thompson, CB .

GENES & DEVELOPMENT, 2003, 17 (15) :1841-1854

[3] Rapamycins - Mechanism of action and cellular resistance [J].

Huang, SL ;

Bjornsti, MA ;

Houghton, PJ .

CANCER BIOLOGY & THERAPY, 2003, 2 (03) :222-232

[4] Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs [J].

Mohi, MG ;

Boulton, C ;

Gu, TL ;

Sternberg, DW ;

Neuberg, D ;

Griffin, JD ;

Gilliland, DG ;

Neel, BG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (09) :3130-3135

[5] Mammalian target of rapamycin inhibition as therapy for hematologic malignancies [J].

Panwalkar, A ;

Verstovsek, S ;

Giles, FJ .

CANCER, 2004, 100 (04) :657-666